Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649854 | 0.87 | HTR2B (0.52) | ALDH1A1ACHEKDM4EHPGDIRAK4 | |
| SCHEMBL6647791 | 0.82 | RAB9A (0.56) | ALDH1A1HPGDCYP19A1 | |
| SCHEMBL3536997 | 0.80 | ACHE (0.66) | ALDH1A1ACHEKDM4EHPGDSPTGER1 | |
| SCHEMBL3538552 | 0.79 | HTR2C (0.56) | ALDH1A1KDM4EHPGDIRAK4 | |
| SCHEMBL6645737 | 0.79 | CYP19A1 (0.39) | ALDH1A1ACHEKDM4EHPGDSHPGD | |
| SCHEMBL15608662 | 0.79 | KDM4E (0.48) | ALDH1A1ACHEKDM4EHPGDSHPGD | |
| SCHEMBL2140447 | 0.78 | KDM4E (0.65) | ALDH1A1ACHEKDM4EHPGDSHPGD | |
| SCHEMBL3823800 | 0.78 | RAB9A (0.59) | ALDH1A1KDM4ECYP19A1DHODHEIF4E | |
| SCHEMBL657641 | 0.77 | ALDH1A1 (0.70) | ALDH1A1KDM4EHPGDSHPGDTDP1 | |
| SCHEMBL3545567 | 0.77 | HTR2C (0.67) | HPGDIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | CYP17A1, CYP21A2, HSD17B1 | ALDH1A1 88/4885ACHE 2039/4885KDM4E 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.